Health Canada
OncologyHERNEXEOS
ZONGERTINIB 60 MG
Condition mapped from Health Canada ATC L01EH04 ZONGERTINIB.
- DIN: 02571730
- Drug code: 107376
- DPD status: Approved
- Therapeutic class: L01EH04 ZONGERTINIB
Condition
Oncology
21 approvals (29 source records) from January 1, 2025 through . Data pulled .
September 2026
August 2026
Health Canada
OncologyPIMJETMI
PIMICOTINIB (PIMICOTINIB HYDROCHLORIDE) 25 MG
Condition mapped from Health Canada ATC L01X OTHER ANTINEOPLASTIC AGENTS.
- DIN: 02569035
- Drug code: 107131
- DPD status: Marketed
- Therapeutic class: L01X OTHER ANTINEOPLASTIC AGENTS
July 2026
Health Canada
OncologyOJEMDA
TOVORAFENIB 100 MG; TOVORAFENIB 25 MG
Condition mapped from Health Canada ATC L01EC04 TOVORAFENIB.
- DIN: 02569817, 02569876
- Drug code: 107202, 107207
- DPD status: Approved
- Therapeutic class: L01EC04 TOVORAFENIB
May 2026
Health Canada
OncologyLUNSUMIO
MOSUNETUZUMAB 1 MG
Condition mapped from Health Canada ATC L01FX25 MOSUNETUZUMAB.
- DIN: 02565226
- Drug code: 106784
- DPD status: Marketed
- Therapeutic class: L01FX25 MOSUNETUZUMAB
April 2026
Health Canada
OncologyHYRNUO
SEVABERTINIB 10 MG
Condition mapped from Health Canada ATC L01EH06 SEVABERTINIB.
- DIN: 02563444
- Drug code: 106622
- DPD status: Marketed
- Therapeutic class: L01EH06 SEVABERTINIB
Health Canada
OncologyTEVIMBRA
TISLELIZUMAB 100 MG
Condition mapped from Health Canada ATC L01FF09 TISLELIZUMAB.
- DIN: 02564009
- Drug code: 106674
- DPD status: Marketed
- Therapeutic class: L01FF09 TISLELIZUMAB
March 2026
Health Canada
OncologyADSTILADRIN
NADOFARAGENE FIRADENOVEC 300000000000 VP
Condition mapped from Health Canada ATC L01XL10 NADOFARAGENE FIRADENOVEC.
- DIN: 02566680
- Drug code: 106917
- DPD status: Approved
- Therapeutic class: L01XL10 NADOFARAGENE FIRADENOVEC
January 2026
Health Canada
OncologyLOQTORZI
TORIPALIMAB 40 MG
Condition mapped from Health Canada ATC L01FF13 TORIPALIMAB.
- DIN: 02562219
- Drug code: 106511
- DPD status: Marketed
- Therapeutic class: L01FF13 TORIPALIMAB
Health Canada
OncologyZIIHERA
ZANIDATAMAB 300 MG
Condition mapped from Health Canada ATC L01FD07 ZANIDATAMAB.
- DIN: 02564610
- Drug code: 106730
- DPD status: Approved
- Therapeutic class: L01FD07 ZANIDATAMAB
Health Canada
OncologyELAHERE
MIRVETUXIMAB SORAVTANSINE 100 MG
Condition mapped from Health Canada ATC L01FX26 MIRVETUXIMAB SORAVTANSINE.
- DIN: 02560771
- Drug code: 106381
- DPD status: Marketed
- Therapeutic class: L01FX26 MIRVETUXIMAB SORAVTANSINE
November 2025
Health Canada
OncologyJAYPIRCA
PIRTOBRUTINIB 50 MG; PIRTOBRUTINIB 100 MG
Condition mapped from Health Canada ATC L01EL05 PIRTOBRUTINIB.
- DIN: 02562006, 02562014
- Drug code: 106492, 106493
- DPD status: Marketed
- Therapeutic class: L01EL05 PIRTOBRUTINIB
October 2025
Health Canada
OncologyVANFLYTA
QUIZARTINIB (QUIZARTINIB HYDROCHLORIDE) 17.7 MG
Condition mapped from Health Canada ATC L01EX11 QUIZARTINIB.
- DIN: 02558351
- Drug code: 106161
- DPD status: Marketed
- Therapeutic class: L01EX11 QUIZARTINIB
August 2025
Health Canada
OncologyAMTAGVI
LIFILEUCEL 72000000000 CELLS
Condition mapped from Health Canada ATC L01XL11 LIFILEUCEL.
- DIN: 02560232
- Drug code: 106331
- DPD status: Approved
- Therapeutic class: L01XL11 LIFILEUCEL
Health Canada
OncologyZYNYZ
RETIFANLIMAB 25 MG
Condition mapped from Health Canada ATC L01FF10 RETIFANLIMAB.
- DIN: 02555239
- Drug code: 104399
- DPD status: Marketed
- Therapeutic class: L01FF10 RETIFANLIMAB
Health Canada
OncologyBLENREP
BELANTAMAB MAFODOTIN 70 MG; BELANTAMAB MAFODOTIN 100 MG
Condition mapped from Health Canada ATC L01FX15 BELANTAMAB MAFODOTIN.
- DIN: 02559617, 02559625
- Drug code: 106275, 106276
- DPD status: Marketed
- Therapeutic class: L01FX15 BELANTAMAB MAFODOTIN
April 2025
Health Canada
OncologyLAZCLUZE
LAZERTINIB (LAZERTINIB MESYLATE) 80 MG; LAZERTINIB (LAZERTINIB MESYLATE) 240 MG
Condition mapped from Health Canada ATC L01EB09 LAZERTINIB.
- DIN: 02555964, 02555972
- Drug code: 104468, 104469
- DPD status: Marketed
- Therapeutic class: L01EB09 LAZERTINIB
Health Canada
OncologyITOVEBI
INAVOLISIB 3 MG; INAVOLISIB 9 MG
Condition mapped from Health Canada ATC L01EM06 INAVOLISIB.
- DIN: 02555476, 02555484
- Drug code: 104427, 104428
- DPD status: Marketed
- Therapeutic class: L01EM06 INAVOLISIB
Health Canada
OncologyVYLOY
ZOLBETUXIMAB 100 MG
Condition mapped from Health Canada ATC L01FX31 ZOLBETUXIMAB.
- DIN: 02553996
- Drug code: 104288
- DPD status: Marketed
- Therapeutic class: L01FX31 ZOLBETUXIMAB
March 2025
Health Canada
OncologyZYNLONTA
LONCASTUXIMAB TESIRINE 10 MG
Condition mapped from Health Canada ATC L01FX22 LONCASTUXIMAB TESIRINE.
- DIN: 02556138
- Drug code: 104483
- DPD status: Approved
- Therapeutic class: L01FX22 LONCASTUXIMAB TESIRINE
Health Canada
OncologyTALVEY
TALQUETAMAB 2 MG; TALQUETAMAB 40 MG
Condition mapped from Health Canada ATC L01FX29 TALQUETAMAB.
- DIN: 02547392, 02547406
- Drug code: 103601, 103602
- DPD status: Marketed
- Therapeutic class: L01FX29 TALQUETAMAB
January 2025
Health Canada
OncologyOJJAARA
MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 100 MG; MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 150 MG; MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) 200 MG
Condition mapped from Health Canada ATC L01EJ04 MOMELOTINIB.
- DIN: 02552965, 02552973, 02552981
- Drug code: 104193, 104194, 104195
- DPD status: Marketed
- Therapeutic class: L01EJ04 MOMELOTINIB